Joint Effects of N-Terminal Pro-B-Type-Natriuretic Peptide and C-Reactive Protein vs Angiographic Severity in Predicting Major Adverse Cardiovascular Events and Clinical Restenosis After Coronary Angioplasty in Patients With Stable Coronary Artery Disease

345 consecutive stable coronary artery disease (CAD) patients who presented with chest pain and positive stress test, and underwent successful percutaneous coronary intervention (PCI). Exclusion criteria: recent myocardial infarction (<2 weeks), acute stroke, overt heart failure (LVEF <35%), severe valvular heart disease, idiopathic cardiomyopathy, serum creatinine >3mg/dl, acute infection, malignancy, and any life-limiting disease.

Measurement of plasma NT-proBNP and CRP levels, and calculation of Gensini score for risk stratification

Major adverse cardiovascular events (MACE) (composite of cardiovascular mortality, MI, and stroke) and cumulative clinical restenosis rate after 18-36-month follow-upcomposite